Pharma BD Deal Intelligence
TKT's enzyme-replacement franchise became the rare-disease core that made Shire itself a $62B target — but Replagal's permanent US market-access failure caps the pipeline story
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Shire agreed to acquire TKT for $37/share ($1.6B), a 22% premium; deal grew out of in-licensing discussions for Dynepo, with $450M break-fee licensing fallback.
Britannic Asset Management (2% Shire holder) opposed the deal saying Shire was 'destroying' value, signaling shareholder concern about the premium and…
Retrospective: Shire experienced 'bad luck moving from pills to proteins' — Dynepo discontinued amid biosimilar competition, Replagal BLA withdrawn 2012.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Shire agrees to acquire TKT for $37/share cash (~$1.6B). Adds Replagal (Fabry) and Dynepo to rare disease portfolio. Shareholders approved July 2005.
TKT's enzyme-replacement franchise became the rare-disease core that made Shire itself a $62B target — but Replagal's permanent US market-access failure caps the pipeline story
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire Pharmaceuticals Group plc / Transkaryotic Therapies, Inc. (TKT) (this deal) | 2005 | $1.6B | 72 |
| Shire Pharmaceuticals Group plc / BioChem Pharma Inc. | 2001 | $4.0B | 33 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2005 deals